Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response - Concepedia

Concepedia

Publication | Closed Access

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

97

Citations

22

References

2006

Year

Paul J. Hesketh, Steven M. Grunberg, Jørn Herrstedt, Ronald de Wit, Richard J. Gralla, A. Carides, Amanda Taylor, Judith K. Evans, Kevin Horgan

Supportive Care in Cancer

Phase Iii TrialsMedicineNk1 Antagonist AprepitantMetronomic TherapyTreatment ResponseClinical PharmacologyPharmacotherapyPharmacology

References

	Year	Citations

Page 1